Comparison of Efficacy of Intravitreal Ranibizumab and Aflibercept in Eyes with Myopic Choroidal Neovascularization: 24-Month Follow-Up

Vascular endothelial growth factor inhibitors for predominantly Caucasian myopic choroidal neovascularization: 2‐year treatment outcomes in clinical practice: data from the Fight Retinal Blindness! Registry

“…We found a similar median number of injections as previous long-term retrospective studies with approximately three-four injections over 24 months (Ng et al 2015;Korol et al 2020). Seventy-five eyes (55%) completing 2 years remained inactive at least 6 months after inactivity.…”

“…Whether mCNV behave differently in Asian and Caucasian eyes, as neovascular age-related macular degeneration does (Mohamed, Gadhvi & Mensah 2018;Kokame et al 2019), is yet to be established. A post-hoc analysis of a subgroup of patients from the RADI-ANCE study [Ranibizumab And PDT (verteporfin) evaluation in mCNV] did not find any visual outcome difference between Caucasian and Asian patients (Holz et al 2016) Korol et al 2020). We also found that older age was significantly associated with poorer visual outcomes.…”

“…Realworld evidence from observational studies is helpful to understand treatment effectiveness and patterns in routine clinical practice and unmet needs in the management of a condition (Sherman et al 2016). Information on long-term treatment outcomes and comparison of VEGF inhibitors for mCNV is still limited to only one RCT, one meta-analysis of prospective case series and a few small comparative and non-comparative observational studies, which included mainly patients of Asian origin (Gharbiya et al 2012;Hayashi et al 2012;Iacono et al 2012;Lai et al 2012;Wang & Chen 2013;Sarao et al 2016;Tan et al 2018;Korol et al, 2020). This study aimed to assess the 24-month treatment outcomes of VEGF inhibitors for mCNV in patients of predominantly Caucasian ethnicity and explore factors that predicted visual function and lesion activity in routine clinical practice.…”

Untitled

“…Anti-vascular endothelial growth factor (VEGF) treatment is currently the most promising preoperative treatment option. Ophthalmologists have gained experience using anti-VEGF agents in the treatment of age-related macular degeneration (AMD), choroidal neovascularization of various origins, diabetic macular edema, and central retinal vein thrombosis [5]. In addition, anti-VEGF agents have been successfully used in combination with vitrectomy in the treatment of patients with PDR [5,6,7].…”

“…Ophthalmologists have gained experience using anti-VEGF agents in the treatment of age-related macular degeneration (AMD), choroidal neovascularization of various origins, diabetic macular edema, and central retinal vein thrombosis [5]. In addition, anti-VEGF agents have been successfully used in combination with vitrectomy in the treatment of patients with PDR [5,6,7]. Particularly, studies have shown complete obliteration of neovascularization within 3-7 days of intravitreal bevacizumab injection, which allowed for a fast and efficacious vitrectomy.…”